GIGABYTE-TECHNOLOGY
3.6.2024 11:31:29 CEST | Business Wire | Press release
Renowned globally for its research and development capabilities, GIGABYTE Technology will exhibit its products and solutions at COMPUTEX from June 4 to June 7 under the theme "ACCEVOLUTION," acclaiming the new era of accelerated-computing and time of AI. AI remains a major trend, attracting industry leaders, including the highest number of CEOs in COMPUTEX history. In celebration, Taipei 101 will be illuminated for COMPUTEX, with GIGABYTE lighting it up on June 4 from 6:30 PM to 10:00 PM, promoting the AI event and welcoming international guests.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240602653282/en/
Shining Bright atop Taipei 101, GIGABYTE Redefines AI Evolution Accelerated by Next-Generation Computing at COMPUTEX (Photo: Business Wire)
Prominent leaders in global chip development will attend COMPUTEX, aiming to assert their influence in the AI era and strengthen ties with the Taiwanese supply chain. GIGABYTE, an integral part of this industry, is honored to invite these CEOs to its booth to explore the latest technologies. GIGABYTE's diverse product lineup spans the entire AI lifecycle, featuring industry-leading technologies and flexible server solutions. These products, designed to meet future computing demands with advanced cooling solutions, will be showcased on an unprecedented scale at COMPUTEX. Additionally, GIGABYTE will present its Red Dot Award-winning PC products, new products demos, and AI experiences for gamers and creators.
GIGABYTE has consistently been the fastest to market with the most diverse range of AI servers. This year, the G593 flagship AI server series, known for its high-density features and flexible design, is displayed to support NVIDIA's next-gen chips H200 and B100, as well as models designed for AMD's MI300X. The showcase will also feature the new X series servers, based on NVIDIA's MGX modular design, which shortens development times and accelerates data center deployment. Customers can choose between AMD EPYC, Intel Xeon x86 CPUs, or NVIDIA Grace Hopper Arm superchips, offering tailored configurations for specific computational needs.
Large Language Models (LLM) have become increasingly popular in AI. To handle the growing number of parameters, GIGABYTE is showcasing servers supporting NVIDIA's latest Blackwell architecture, featuring the highly acclaimed high-density designs with the powerful B100 and B200 superchips. The B100 will be compatible with the G593 series hardware, while the B200's next-level performance introduces thermal challenges beyond the capacity of traditional air cooling. GIGABYTE has addressed this with its industry-leading thermal engineering by employing direct liquid cooling. The highly anticipated GB200 will also be demonstrated in a liquid-cooled cabinet as the GB200 NVL72, acting as a massive GPU that can achieve 30 times the inference performance of an equivalent number of H100 GPUs. This allows visitors not only to witness these innovations firsthand but also to engage in discussions about the future of AI development and computing deployment.
Introducing GIGA POD, GIGABYTE’s one-stop rack integration solution leveraging its 20+ years of server proficiency and experience gained from CSP partnerships. GIGA POD is a complete system integration including architecture planning, equipment integration, software installation, and post-deployment testing. It offers different configurations of AI servers with NVIDIA SXM or AMD Instinct GPUs or NVIDIA Superchips and is gradually expanding to future top-tier GPU-equipped AI servers. GIGA POD is also a prime demonstration of GIGABYTE’s thermal engineering, fitting an HGX module in a 5U chassis of an air-cooled G593 server. Such dense server enables customers the option to choose either a 9-rack configuration with 4 AI servers per 42U rack or a 5-rack configuration with 8 AI servers per 48U rack, achieving nearly double the utilization space and greatly improving resource efficiency. GIGABYTE has also invited Northern Data Group, a key client of its cluster computing solution (GIGA POD) and Europe’s largest generative AI cloud service provider, to participate in a special event "Executive Dialogue with AI Visionaries" with the General Manager of GIGABYTE's subsidiary, Giga Computing. The live conversation will cover the collaboration, keys to success, and perspectives on the future of AI.
AI development extends beyond GPU computations to comprehensive data center infrastructure, including storage and network transmission. GIGABYTE's R&D expertise in thermal, mechanical, and modular design ensures a diverse product range across IT architectures. At COMPUTEX, GIGABYTE will showcase servers for cloud and edge computing, high-performance, and high-density storage. Additionally, general-purpose servers for SMBs and DIY server motherboards for micro-enterprises and individuals will be displayed, supporting AI development at all scales.
GIGABYTE has pioneered advanced cooling solutions, mastering technologies like direct liquid and immersion cooling. With expertise in cross-disciplinary integration, GIGABYTE has developed its own cold plates, DLC racks, and immersion tanks, offering comprehensive cooling solutions. At COMPUTEX, GIGABYTE will showcase single-phase immersion cooling, direct liquid cooling, and a new rear-door heat exchanger (RDHx) cooling rack. Collaborating with nVent, GIGABYTE deployed Spain's third-ranked supercomputer, Hyperion, using full-rack servers with RDHx. This setup, connected to an outdoor chiller, delivers up to 54,000 watts of heat dissipation per hour, reducing air conditioning needs and effectively managing computational hotspots.
GIGABYTE presents both robust AI model training capabilities and practical AI applications through industrial-grade embedded computers. Demonstrations span smart factories with AI-enabled machine vision and high-stability embedded computers for remote control, as well as retail bars utilizing panel PCs combined with AI recognition and big data analysis. Advancements in AI and next-generation CPU/GPU also bolster smart automotive applications, enhancing ADAS and in-vehicle Telematics devices.
The rise of AI is transforming personal computing. GIGABYTE's Z790 series motherboards are designed for different scenarios, and support RTX 40 SUPER series graphics cards, deliver peak performance with enhanced core counts, VRAM, and memory speeds. Utilizing AI acceleration, the graphics cards offer exceptional computing and graphics processing for both professional tasks and AAA gaming, while preparing users for new AI-driven applications. The AORUS 17X and 16X AI laptops feature GIGABYTE's AI Nexus with AI Boost, AI Generator, and AI Power Gear, providing improved performance, seamless AI generation, and extended battery life. At our booth's AI experience area, visitors can explore the latest AI applications and real-time interactions, including NVIDIA ACE and ChatRTX, delving immersively into cutting-edge AI technologies.
Visit GIGABYTE’s COMPUTEX event page.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240602653282/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
